Status:
COMPLETED
Gout Self-Monitoring Aiming to Reach Target
Lead Sponsor:
University of Edinburgh
Conditions:
Gout
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study evaluates whether a supported self-management approach to gout is able to achieve target levels of serum urate, and better control of gout flares.
Detailed Description
Gout is the most common cause of inflammatory arthritis with recurrent gout flares a cause of reduced quality of life, work absence and disability. Effective treatments are widely available and yet ma...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of gout (as per American College of Rheumatology criteria)
- Physician recommendation that escalation of urate lowering therapy with allopurinol or febuxostat is appropriate.
- Serum urate \>0.36mm/L.
- Patient has a mobile phone and is able to install GoutSMART (Gout Self-monitoring Aiming to Reach Target urate) application.
Exclusion
- Subject is unable to provide consent
- Severe renal failure (eGFR \<30) or established liver disease
- Previous adverse reaction to allopurinol or febuxostat
Key Trial Info
Start Date :
April 5 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03274063
Start Date
April 5 2019
End Date
June 1 2021
Last Update
May 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Western General Hospital
Edinburgh, United Kingdom, EH4 2XU